EXPAREL is now an opioid-free option for use as an interscalene brachial plexus block for upper extremity surgeries Conference call on Monday, April 9, 2018 at 8:30 a.m. EST PARSIPPANY, N.J., April 06 ...
The Food and Drug Administration (FDA) has approved the use of Exparel (bupivacaine liposome injectable suspension; Pacira Pharmaceuticals) as an interscalene brachial plexus block to produce ...
In both studies, Exparel achieved a statistically significant reduction in cumulative pain scores from 0 to 96 hours compared with bupivacaine hydrochloride. The Food and Drug Administration (FDA) has ...
— EXPAREL is the only FDA-approved single-dose regional analgesic to safely demonstrate four days of superiority versus bupivacaine in two clinical studies — — New indications for use as an adductor ...
--EXPAREL is the first long-acting non-opioid option for field block and brachial plexus or femoral nerve block approved in Europe-- “We are pleased to see news of the European Commission’s approval ...
Ultrasound-guided peripheral nerve blocks have a higher success rate compared to nerve stimulation or other methods, according to a study conducted by the Department of Anesthesiology at Johns Hopkins ...
PARSIPPANY, N.J., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NADSAQ: PCRX), the leading global provider of non-opioid pain management options, today announced that the European ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback